ARIA
Income statement / Annual
Last year (2015), ARIAD Pharmaceuticals, Inc.'s total revenue was $118.80 M,
an increase of 12.70% from the previous year.
In 2015, ARIAD Pharmaceuticals, Inc.'s net income was -$231.16 M.
See ARIAD Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
FY-2010
|
FY-2009
|
FY-2008
|
FY-2007
|
FY-2006
|
| Period Ended |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
12/31/2010 |
12/31/2009 |
12/31/2008 |
12/31/2007 |
12/31/2006 |
| Operating Revenue |
$118.80 M |
$105.41 M |
$45.56 M |
$558.00 K |
$25.30 M |
$178.98 M |
$8.30 M |
$7.08 M |
$3.58 M |
$896.00 K |
| Cost of Revenue |
$2.11 M
|
$5.22 M
|
$9.61 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$116.69 M
|
$100.19 M
|
$35.95 M
|
$558.00 K
|
$25.30 M
|
$178.98 M
|
$8.30 M
|
$7.08 M
|
$3.58 M
|
$896.00 K
|
| Gross Profit Ratio |
0.98
|
0.95
|
0.79
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$171.22 M
|
$120.59 M
|
$162.90 M
|
$144.71 M
|
$77.74 M
|
$57.99 M
|
$63.45 M
|
$50.84 M
|
$39.57 M
|
$43.31 M
|
| General & Administrative Expenses |
$162.75 M
|
$139.79 M
|
$146.62 M
|
$60.91 M
|
$24.38 M
|
$16.10 M
|
$16.89 M
|
$28.09 M
|
$24.71 M
|
$21.25 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$162.75 M
|
$139.79 M
|
$146.62 M
|
$60.91 M
|
$24.38 M
|
$16.10 M
|
$16.89 M
|
$28.09 M
|
$24.71 M
|
$21.25 M
|
| Other Expenses |
$2.11 M
|
$5.22 M
|
$9.61 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$336.08 M
|
$265.61 M
|
$319.13 M
|
$205.62 M
|
$102.12 M
|
$74.08 M
|
$80.34 M
|
$78.93 M
|
$64.28 M
|
$64.56 M
|
| Cost And Expenses |
$338.19 M
|
$270.83 M
|
$328.74 M
|
$205.62 M
|
$102.12 M
|
$74.08 M
|
$80.34 M
|
$78.93 M
|
$64.28 M
|
$64.56 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$18.15 M
|
$8.08 M
|
$153.00 K
|
$199.00 K
|
$232.00 K
|
$206.00 K
|
$287.00 K
|
$550.00 K
|
$337.00 K
|
$483.00 K
|
| Depreciation & Amortization |
$12.76 M
|
$8.81 M
|
$4.14 M
|
$8.31 M
|
$4.61 M
|
$6.15 M
|
$4.22 M
|
$3.02 M
|
$2.31 M
|
$4.63 M
|
| EBITDA |
-$203.65 M |
-$145.08 M |
-$269.43 M |
-$212.37 M |
-$118.76 M |
$91.60 M |
-$75.50 M |
-$67.49 M |
-$55.88 M |
-$56.81 M |
| EBITDA Ratio |
-1.71
|
-1.38
|
-5.91
|
-380.58
|
-4.69
|
0.51
|
-9.09
|
-9.53
|
-15.6
|
-63.41
|
| Operating Income Ratio |
-1.83
|
-1.52
|
-6
|
-367.49
|
-3.04
|
0.59
|
-8.68
|
-10.15
|
-16.94
|
-71.06
|
| Total Other Income/Expenses Net |
-$17.27 M
|
-$1.78 M
|
-$153.00 K
|
-$15.81 M
|
-$46.78 M
|
-$19.65 M
|
-$7.98 M
|
$799.00 K
|
$2.17 M
|
$1.74 M
|
| Income Before Tax |
-$234.55 M
|
-$161.97 M
|
-$273.72 M
|
-$220.87 M
|
-$123.60 M
|
$85.25 M
|
-$80.01 M
|
-$71.05 M
|
-$58.52 M
|
-$61.93 M
|
| Income Before Tax Ratio |
-1.97
|
-1.54
|
-6.01
|
-395.83
|
-4.89
|
0.48
|
-9.64
|
-10.03
|
-16.33
|
-69.12
|
| Income Tax Expense |
-$3.39 M
|
$630.00 K
|
$439.00 K
|
-$15.61 M
|
-$46.55 M
|
-$19.45 M
|
-$7.69 M
|
$1.35 M
|
$2.51 M
|
$2.22 M
|
| Net Income |
-$231.16 M
|
-$162.60 M
|
-$274.16 M
|
-$220.87 M
|
-$123.60 M
|
$85.25 M
|
-$80.01 M
|
-$71.05 M
|
-$58.52 M
|
-$61.93 M
|
| Net Income Ratio |
-1.95
|
-1.54
|
-6.02
|
-395.83
|
-4.89
|
0.48
|
-9.64
|
-10.03
|
-16.33
|
-69.12
|
| EPS |
-1.21 |
-0.85 |
-1.44 |
-1.34 |
-0.93 |
0.75 |
-0.86 |
-1.02 |
-0.86 |
-0.99 |
| EPS Diluted |
-1.21 |
-0.85 |
-1.44 |
-1.34 |
-0.93 |
0.75 |
-0.86 |
-1.02 |
-0.86 |
-0.99 |
| Weighted Average Shares Out |
$190.89 M
|
$190.89 M
|
$190.89 M
|
$164.96 M
|
$132.38 M
|
$113.02 M
|
$93.33 M
|
$69.79 M
|
$68.22 M
|
$62.68 M
|
| Weighted Average Shares Out Diluted |
$190.89 M
|
$190.89 M
|
$190.89 M
|
$164.96 M
|
$132.38 M
|
$113.02 M
|
$93.33 M
|
$69.79 M
|
$68.22 M
|
$62.68 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
